EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination

Yesseinia I Anglero-Rodriguez, Florian A Lempp, Megha Subramanian, James McIninch, Mark K Schlegel iD, Dana Bohan, Emily Wong, Christopher R Brown iD, Donald J Foster, Adam B Castoreno, Tuyen Nguyen, Dara Cuffe und 31 weitere

Nucleic Acids Research · 2025

DOI: 10.1093/nar/gkae1195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Yesseinia I Anglero-Rodriguez und 42 weiteren Autor:innen. Beteiligte Einrichtung: Alnylam Pharmaceuticals; Cambridge, MA 002142, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, RNA, Small Interfering, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: H.W.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA interference is a natural antiviral mechanism that could be harnessed to combat SARS-CoV-2 infection by targeting and destroying the viral RNA. We identified potent lipophilic small interfering RNA (siRNA) conjugates targeting highly conserved regions of SARS-CoV-2 outside of the spike-encoding region capable of achieving ≥3-log viral reduction. Serial passaging studies demonstrated that a two-siRNA combination prevented development of resistance compared to a single siRNA approach. Viral resistance to single siRNA treatment occurred due to emergence of point mutations at critical positions required for siRNA-mediated target binding and cleavage, which led to a loss of siRNA efficacy. With a two-siRNA combination, emergence of mutations within the siRNA binding site was abolished. When delivered intranasally, two-siRNA combination protected Syrian hamsters from weight loss and lung pathology by viral infection upon prophylactic administration but not following onset of infection. Together, the data support potential utility of RNAi as a prophylactic approach with high resistance barrier to counteract SARS-CoV-2 emergent variants and complement vaccination. Most importantly, given that the siRNAs can be rapidly developed from a new pathogen sequence, this strategy has implications as a new type of preventive medicine that may protect against future coronavirus pandemics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2RNA, Small InterferingCOVID-19AnimalsHumansCricetinaeMesocricetusRNA InterferenceDisease Models, AnimalSpike Glycoprotein, CoronavirusRNA, ViralVero CellsChlorocebus aethiops

Substanzen

RNA, Small InterferingSpike Glycoprotein, CoronavirusRNA, Viralspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Alnylam Pharmaceuticals; Cambridge, MA 002142, USA.
  • Vir Biotechnology Inc.; San Francisco, CA 94158, USA.
  • Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Mark K Schlegel, Christopher R Brown, Ivan Zlatev, Jayaprakash Nair, Martin A Maier, Vasant Jadhav

Förderung

  • H.W.V.

Zitieren

APA

Anglero-Rodriguez, Y. I., Lempp, F. A., Subramanian, M., McIninch, J., Schlegel, M. K., Bohan, D., Wong, E., Brown, C. R., Foster, D. J., Castoreno, A. B., Nguyen, T., Cuffe, D., Montiel-Ruiz, M., Kaiser, H., Sahakyan, A., Spreafico, R., Morskaya, S. S., Barry, J. D., Berman, D., …, & Jadhav, V. (2025). High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae1195

Vancouver

Anglero-Rodriguez YI, Lempp FA, Subramanian M, McIninch J, Schlegel MK, Bohan D, et al. High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination. Nucleic Acids Research. 2025. doi:10.1093/nar/gkae1195

BibTeX
@article{AngleroRodriguez2025,
  author = {Anglero-Rodriguez, Yesseinia I and Lempp, Florian A and Subramanian, Megha and McIninch, James and Schlegel, Mark K and Bohan, Dana and Wong, Emily and Brown, Christopher R and Foster, Donald J and Castoreno, Adam B and Nguyen, Tuyen and Cuffe, Dara and Montiel-Ruiz, Martin and Kaiser, Hannah and Sahakyan, Anna and Spreafico, Roberto and Morskaya, Svetlana Shulga and Barry, Joseph D and Berman, Daniel and Zhang, Ligang and Lefebvre, Stephanie and Kasper, Anne and Racie, Timothy and Weddle, Diann and Mobley, Melissa and Wassarman, Kelly and Bisbe, Anna and Zlatev, Ivan and Rogers, Arlin and Nechev, Lubomir and Dybowski, Joseph and Chong, Saeho and Nair, Jayaprakash and Simon, Amy and Sloan, Kevin and Hwang, Seungmin and Virgin, Herbert W and Fitzgerald, Kevin and Maier, Martin A and Hinkle, Gregory and Hebner, Christy M and Akinc, Akin and Jadhav, Vasant},
  title = {High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination},
  journal = {Nucleic Acids Research},
  year = {2025},
  doi = {10.1093/nar/gkae1195}
}
Kostenlos starten →